Table 6.

Carfilzomib responses in multiple Myeloma, Waldenström's Macroglobulinemia, and non–Hodgkin lymphoma patients

Patient ID, by diseasea categoryResponseDisease subtypeStarting dose, mg/m2Dose atdiscontinuation, mg/m2Duration on study, dLast prior treatment
Dose escalation
MM (n = 20)
 2-02-004SD2.420409BTZ
 2-06-002SDIgG6.02071BTZ/Dex
 2-01-005PRIgG1520392SCT
 2-01-007SDIgG202062CTX/Pred
 2-01-008PRIgG2020224BTZ
 2-01-009PRIgA2727334BTZ/tipifarnib
 2-01-011MRIgG2727134Len/Dex
 2-01-012PRIgG2720259BTZ
 2-06-004SDIgG2727225CTX/Pred
NHL (n = 15)
 2-02-008SDFL4.020387NA
 2-02-010SDFL6.020352NA
 2-02-011SDSLL/CLL8.420317NA
 2-02-012SDFL111168NA
 2-02-021SDFL2020128NA
Dose expansion
MM (n = 6)
 2-01-020PRIgG20/2720/27324Thal/Dex
 2-31-001MRIgG20/27 + Dex20/27 + Dex324BTZ/Dex/PD0332991
 2-01-019SDIgG20/2720/27121Sorafenib
WM (n = 2)
 2-07-001PRIgM20/2720/27156Rituximab
 2-31-003SDIgM20/2720/2767BTZ/Dex/CTX

Abbreviations: BTZ, bortezomib; CFZ, carfilzomib; CTX, cyclophosphamide; Dex, dexamethasone; Gem, gemcitabine; Len, lenalidomide; MM, multiple myeloma; MR, minimal response; NA, not applicable; NHL, non–Hodgkin lymphoma; PR, partial response; Pred, prednisone; SCT, stem cell transplant; SD, stable disease; WM, Waldenström's macroglobulinemia.

  • aThe single patient with HL was not a responder and is not included in the table.